HC Wainwright Has Optimistic Outlook of MSLE Q2 Earnings

Satellos Bioscience Inc. (NASDAQ:MSLE) – Equities researchers at HC Wainwright boosted their Q2 2026 earnings estimates for shares of Satellos Bioscience in a research report issued on Monday, March 30th. HC Wainwright analyst A. He now forecasts that the company will earn ($0.36) per share for the quarter, up from their prior estimate of ($0.48). HC Wainwright currently has a “Buy” rating and a $11.00 target price on the stock. HC Wainwright also issued estimates for Satellos Bioscience’s Q3 2026 earnings at ($0.37) EPS, Q4 2026 earnings at ($0.37) EPS, FY2026 earnings at ($1.45) EPS, Q1 2027 earnings at ($0.40) EPS, Q2 2027 earnings at ($0.43) EPS, Q3 2027 earnings at ($0.46) EPS, Q4 2027 earnings at ($0.50) EPS, FY2027 earnings at ($1.78) EPS, FY2028 earnings at ($1.89) EPS and FY2029 earnings at ($1.21) EPS.

Satellos Bioscience (NASDAQ:MSLE) last announced its quarterly earnings data on Friday, March 27th. The company reported ($0.47) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.11).

A number of other equities analysts have also recently commented on the company. Wall Street Zen cut Satellos Bioscience to a “strong sell” rating in a report on Saturday, March 14th. Weiss Ratings assumed coverage on Satellos Bioscience in a research report on Wednesday, February 11th. They issued a “sell (d-)” rating on the stock. Zacks Research raised Satellos Bioscience to a “hold” rating in a research note on Tuesday, February 10th. Finally, Cantor Fitzgerald started coverage on shares of Satellos Bioscience in a report on Wednesday, March 11th. They issued an “overweight” rating for the company. Two equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $11.00.

Satellos Bioscience Stock Performance

Shares of MSLE stock opened at $5.87 on Wednesday. The firm has a market capitalization of $90.75 million, a price-to-earnings ratio of -3.79 and a beta of 1.37. Satellos Bioscience has a fifty-two week low of $4.53 and a fifty-two week high of $13.39.

Trending Headlines about Satellos Bioscience

Here are the key news stories impacting Satellos Bioscience this week:

• Positive Sentiment: HC Wainwright reaffirmed a “Buy” rating and a $11 price target, explicitly forecasting upside for MSLE which supports investor optimism. HC Wainwright Forecasts Strong Price Appreciation for Satellos Bioscience (NASDAQ:MSLE) Stock
• Positive Sentiment: The same HC Wainwright note raised several near-term EPS forecasts (Q2–Q4 2026 and multiple quarters in 2026–2027, plus an improved FY2026 and FY2027 view), indicating the firm sees operating improvements in the next 12–18 months — a constructive signal for growth-oriented investors.
• Neutral Sentiment: Coverage includes longer-horizon analyst projections (including FY2030 forecasts), which provide modeling inputs but are distant and carry greater uncertainty; these projections alone are unlikely to move shares materially without nearer-term catalysts. Analysts Offer Predictions for MSLE FY2030 Earnings
• Negative Sentiment: HC Wainwright cut some near-term/longer-term estimates: Q1 2027 was lowered, and FY2028 and FY2029 EPS views were revised to be more negative — signaling cost or timing risks that could pressure sentiment. Also, Satellos missed the last reported quarter (EPS miss vs. consensus), a near-term negative for the stock.

Satellos Bioscience Company Profile

Satellos Bioscience Inc is a regenerative medicine company dedicated to developing novel therapeutics which stimulate or restore muscle regeneration in severe disorders. The company’s lead program is focused on developing an oral therapeutic drug for Duchenne muscular dystrophy. Satellos Bioscience Inc, formerly known as iCo Therapeutics Inc, is based in Toronto, Ontario.